Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

ALK+ Advanced NSCLC × brigatinib × Thoracic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 20 Lung Neoplasms 9 Carcinoma 3 Carcinoma, Squamous Cell 2 Carcinoma, Large Cell 2 Adenocarcinoma 2 ALK-positive Advanced NSCLC 2 Sexual Dysfunction, Physiological 1 Neoplasms 1 NSCLC 1 Lymphoma, Large-Cell, Anaplastic 1 Gastrointestinal Neoplasms 1 Eunuchism 1 Erectile Dysfunction 1 Disease Progression 1 Breast Neoplasms 1 Brain Neoplasms 1 ALK-positive NSCLC 1 ALK+ Advanced NSCLC 1

Interventions

brigatinib 1 alectinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03596866 2025-09-12

ALTA-3

Takeda

Phase 3 Completed

248 enrolled 20 charts

ALK+ Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡